Molecure KITE trial clears interim review with no protocol changes
Molecure S.A. has received a positive recommendation from its Independent Data Monitoring Committee to continue the KITE Phase II trial of OATD-01 in active pulmonary sarcoidosis without altering the study protocol. The Warsaw-listed company said the IDMC reached its conclusion after reviewing unblinded safety and efficacy data from the first 30 patients enrolled in the double-blind, placebo-controlled study.
The interim futility analysis indicated that the trial retains a sufficient probability of achieving its primary endpoint, which is based on differences measured through PET/CT imaging. Separately, a blinded biomarker analysis covering 23 patients showed inflammatory marker trends that the company described as consistent with OATD-01's expected biological activity, though Molecure cautioned that firm conclusions cannot be drawn until the study is unblinded.
Trial design and next steps
KITE is being conducted across nearly 30 sites in the United States, the EU, Norway, and the UK. Patients receive either a fixed 25 mg dose of OATD-01 or placebo over a 12-week treatment period. Molecure said it is currently randomising 20 additional patients for a second and final interim analysis, which will include a statistical re-evaluation of the required overall sample size.
Marcin Szumowski, chief executive of Molecure, said the committee's decision "suggests that the study has a good chance of achieving its primary efficacy endpoint and meets the required safety criteria," and added that the result strengthens the company's position in ongoing partnering discussions following interest generated at the BIO International Convention.
Daniel Culver, a pulmonary sarcoidosis specialist at the Cleveland Clinic, said he was "highly impressed with the biomarker data," noting they were "consistent with the possibility that there are between-group differences related to the study drug for biomarkers of sarcoidosis inflammation."
Market context and competitive landscape
OATD-01 is described by Molecure as a first-in-class inhibitor of CHIT1, the enzyme chitotriosidase-1, which is implicated in granulomatous inflammation. Pulmonary sarcoidosis is a rare interstitial lung disease with no approved disease-modifying therapies; current management relies largely on corticosteroids, which carry significant long-term toxicity. That unmet-need profile makes the indication attractive to developers, though the clinical path is complicated by the disease's variable natural history and the lack of validated surrogate endpoints beyond imaging.
Molecure is not alone in targeting interstitial lung diseases through novel mechanisms. A number of biotechs, including larger pharmaceutical players, are pursuing anti-fibrotic and anti-inflammatory approaches in adjacent indications such as idiopathic pulmonary fibrosis. Molecure's own pipeline includes OATD-02, a dual arginase inhibitor in Phase I for oncology, which suggests the company is building a broader platform rather than a single-asset story. Whether the CHIT1 mechanism can differentiate OATD-01 sufficiently to attract a licensing partner will depend heavily on the unblinded readout from KITE.
Investors watching for the next value inflection point should focus on the timing of the second interim analysis, which will determine whether the planned sample size needs to be adjusted upward. A sample-size increase would extend the timeline and raise capital requirements; confirmation of the current size would support a faster path to a potential Phase III decision.
The positive IDMC recommendation, while procedurally routine in well-run trials, is nonetheless meaningful here because it confirms the study's safety profile remains acceptable and that the trial is not being declared futile at the halfway stage. For a small-cap company running a global multi-site study, that signal supports both recruitment momentum and the partnership conversations Molecure has publicly flagged.